Theraclion (XPAR:ALTHE) ROCE % : -23.37% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Theraclion ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Theraclion's annualized ROCE % for the quarter that ended in Dec. 2023 was -23.37%.

Theraclion ROCE % Historical Data

The historical data trend for Theraclion's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theraclion ROCE % Chart

Theraclion Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-78.12

-61.79

-69.17

-66.10

-39.54

Theraclion Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-75.24	-56.49	-50.29	-47.07	-23.37

Theraclion ROCE % Calculation

Theraclion's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-4.693	/	( ( (13.943 - 4.317)	+	(18.664 - 4.555) )	/ 2 )
	=	-4.693	/	( (9.626	+	14.109)	/ 2 )
	=	-4.693	/	11.8675
	=	-39.54 %

Theraclion's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-3.464	/	( ( (20.873 - 5.338)	+	(18.664 - 4.555) )	/ 2 )
	=	-3.464	/	( ( 15.535	+	14.109 )	/ 2 )
	=	-3.464	/	14.822
	=	-23.37 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Theraclion (XPAR:ALTHE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Theraclion ROCE % Related Terms

Thank you for viewing the detailed overview of Theraclion's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theraclion (XPAR:ALTHE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theraclion (XPAR:ALTHE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

102, rue Etienne Dolet, Malakoff, FRA, 92240

Website

http://www.theraclion.com

Theraclion is a France-based company specializing in high-tech therapeutic ultrasound equipment. The product, Echopulse, helps in the treatment of breast fibroadenomas and benign thyroid nodules.

Theraclion (XPAR:ALTHE) Headlines

No Headlines